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Insulin-like growth factors (IGF)-I and -II are potent mitogens to
breast cancer cell lines and may prevent apoptosis (Karey and
Sirbasku, 1988; Resnicoff et al, 1995). The type I IGF-receptor
(IGF-IR), which mediates these signals, is found to be expressed
in most human breast cancers (Peyrat et al, 1988), and its expres-
sion is enhanced by oestrogens in ER+ breast cancer cell lines
(Wiseman et al, 1993; Huynh et al, 1996). 
Several studies have suggested a role for the IGFs in breast
cancer growth and tumour development. High plasma levels of
total IGF-I have been associated with an elevated risk for breast
cancer in premenopausal women (Hankinson et al, 1998) and also
for prostate cancer in males (Chan et al, 1998). Other investigators
have reported alterations in the IGF-system in breast cancer
patients including elevated levels of total IGF-I, reduced levels of
IGF-binding protein-3 and an elevated IGF-I/IGFBP-3 ratio
compared to healthy individuals (Peyrat et al, 1993; Bruning et al,
1995). Recently, increased expression of the type I IGF receptor in
the tumour has been related to local relapse following radiotherapy
in breast cancer patients (Turner et al, 1997). 
Most plasma IGF-I and -II are bound in a ternary complex
consisting of IGFBP-3 and an acid-labile subunit (ALS). Due to its
long half-life (Guler et al, 1989), this complex is thought to act as
a depot of IGF-I and -II in plasma (Jones and Clemmons, 1995).
Proteases having IGFBP-3 as substrate may increase the bioavail-
able fraction of IGF-I by decreasing the binding affinity of IGFBP-
3 for the growth factors (Blat et al, 1994), resulting in a drop in
plasma total IGF-I levels (Cotterill et al, 1996). 
An increased IGFBP-3 protease activity has been described in
certain pathological conditions like diabetes (Bereket et al, 1995),
severe illness (Davies et al, 1991), but also in patients suffering
from advanced malignancies, including breast cancer (Frost et al,
1996). If this also occurs for patients with early breast cancer, it
could make total IGF-I an unreliable predictor of bioavailable
IGF-I in these patients. Previous findings from our group have also
indicated IGFBP-3 proteolysis to correlate to tumour burden in
metastatic breast cancer (Helle et al, 1996). An elevated protease
activity might have a detrimental positive feedback effect on
tumour growth by facilitating the release of IGF-I to the tissues
(Blat et al, 1994). 
The main purpose of this study was: 
(1) To determine whether plasma IGFBP-3 proteolysis was
elevated in patients with primary breast cancer. 
(2) If so, to test the hypothesis that an elevated IGFBP-3 proteol-
ysis might correlate to tumour burden. 
(3) To evaluate the possible influence of IGFBP-3 proteolysis on
plasma levels of free IGF-I. 
PATIENTS AND METHODS 
Patients 
A total of 128 women referred to the breast unit at the Department
of Surgery, Haukeland University Hospital due to suspected or
manifest breast cancer were enrolled in the study. 
Age, stage distribution, and treatment of the patients are shown
in Table 1. As blood samples were obtained before definitive
histological diagnosis and staging were performed, 12 patients
turned out to have a benign condition or ductal carcinoma in situ
while 15 patients had metastatic disease at primary diagnosis.
None of the stage IV patients had any history of breast cancer
Plasma insulin-like growth factor binding protein-3
proteolysis is increased in primary breast cancer 
SI Helle1, S Geisler1, T Aas2, T Paulsen2, JMP Holly3 and PE Lønning1
1Department of Oncology and 2Surgery, Haukeland University Hospital, N-5021 Bergen, Norway; 3Division of Surgery, Bristol Royal Infirmary, Bristol BS2 8HW,
UK
Summary Fasting blood samples were obtained before definitive surgery or biopsy in 128 patients referred to the department of surgery 
with suspected or manifest breast cancer. Insulin-like growth factor (IGF)-I, IGF-II and free IGF-I were measured by radioimmuno-
assay/immunoradiometric assay, while IGFBP-3 proteolysis was evaluated by Western immunoblot. 12 patients had ductal carcinoma in situ benign
conditions, while staging revealed metastatic disease in 15 of 16 patients with invasive cancers. IGFBP-3 proteolysis above the normal range was
recorded in 19 patients with invasive cancers, but in none of the patients suffering from DCIS/benign conditions. Increased IGFBP-3 proteolysis was
most frequently recorded in patients harbouring large tumours and metastatic disease (Stage I: 0/19, 0%; Stage II: 3/45, 7%, Stage III: 9/37, 24%,
and Stage IV: 7/15, 47%). IGFBP-3 proteolysis was significantly higher in Stage III (P=0.01) and IV (P< 0.001)  patients compared to the other
stage groups (P = 0.001). IGF-I and IGF-II correlated negatively to IGFBP-3 proteolysis and age. Plasma levels of IGF-I and -II were significantly
lower in patients with elevated IGFBP-3 proteolysis compared to those within the normal range. Our findings reveal alterations in the IGF-system
among a substantial number of patients with large primary breast cancers. © 2001 Cancer Research Campaign http://www.bjcancer.com
Keywords: insulin-like growth factor binding protein-3; proteolysis; insulin-like growth factor-I; primary breast cancer 
74
Received 27 November 2000 
Revised 5 March 2001 
Accepted 20 March 2001 
Correspondence to: PE Lønning 
British Journal of Cancer (2001) 85(1), 74–77
© 2001 Cancer Research Campaign
doi: 10.1054/ bjoc.2001.1860, available online at http://www.idealibrary.com on  http://www.bjcancer.comThe IGF-system in primary breast cancer 75
British Journal of Cancer (2001) 85(1), 74–77 © 2001 Cancer Research Campaign
before referral. Noteworthy, the stage distribution in our study
does not reflect the stage distribution of breast cancer in the
Norwegian population in general, as the Department of Surgery is
a referral unit having patients with locally advanced disease in
particular referred from other clinics. While none of the patients
had any uncontrolled metabolic or other serious disease at the time
of study inclusion, 7 patients suffered from different diseases that
could possibly have an influence on the IGF-system. These
included rheumatoid arthritis (2 patients), ulcerative colitis (1
patient) or type II diabetes (4 patients). 
Each patient gave her informed consent before inclusion. The
protocol was approved by the Regional Ethical Committee. 
Blood sampling 
All patients had fasting blood samples obtained between 07.30 and
08.30 am at the day of biopsy or definitive operation. Patients with
locally advanced disease (T3–4) or T2N2 had samples collected
before start of chemotherapy. Samples were collected in
heparinized vials. Centrifugation was performed within 30
minutes and plasma stored at –20°C until analysis. 
Control group 
As a control group we prospectively collected plasma samples
from 114 normal postmenopausal women attending a mammog-
raphy screening program. Women with a history of diabetes or
endocrine disease were excluded. Median age was 66 years (range
55–72). We also obtained fasting plasma samples from 39 healthy
premenopausal women from the hospital staff with median age 31
years (range 23–43). The normal ranges of the IGF-parameters are
based on the 95% confidence intervals of the individual observa-
tions. 
Assays 
Plasma levels of IGF-I and IGF-II were measured by RIA
following acid-acetone extraction (Frost et al, 1996). Intra- and
inter-assay coefficients of variations in our lab were 3.5% and
6.2% for IGF-I and 5.5% and 12.9% for IGF-II, respectively. Free
IGF-I was measured by an immunoradiometric assay kit purchased
from Diagnostic System Laboratories (Webster, TX) according to
the manufacturers instructions. Intra-assay coefficient of variation
in our control plasma pool from postmenopausal women was 13%. 
IGFBP-3 proteolysis was measured indirectly by Western
immunoblots as IGFBP-3 fragmentation (Frost et al, 1996). This
was defined as the ratio of the major IGFBP-3 fragment (30 kDa)
to total IGFBP-3 evaluated by densitometric scanning of
immunoblots for IGFBP-3. The smaller occasional IGFBP-3
fragments of 20 and 16 kDa were not taken into account when
calculating IGFBP-3 proteolysis. Intra- and inter-assay coeffi-
cients of variations in our control plasma pool were 4.6% and
15.5% respectively. 
Statistics 
Values of the different IGF-parameters measured in normal pre-
and postmenopausal women were tested separately for their distrib-
ution with use of Quartile-Quartile (Q-Q) plots (Johnson and
Wichern, 1982). All parameters were found to be best fitted to a log
normal distribution with the exception of the IGFBP-3 proteolysis,
which was best described by a normal distribution. Thus, parame-
ters obtained in the different groups of patients are given as their
geometric mean value with 95% confidence intervals of the mean,
with the exception of IGFBP-3 proteolysis where the arithmetic
mean values are given. Thus, the normal range (95% confidence
interval) of the individual observations for the plasma IGFBP-3
proteolysis was defined as a ratio of fragmented to total IGFBP-3
of 0.26–0.52 for premenopausal women and 0.22–0.58 for post-
menopausal women. Patients having values above the normal
range (0.52 for premenopausal and 0.58 for postmenopausal
women) were considered to have an elevated plasma IGFBP-3
proteolysis. The Chi-square test including Yates correction for
small numbers was used to compare the frequency of elevated
IGFBP-3 fragmentation among patients with invasive breast carci-
nomas (stage I–IV). IGF values obtained from patients with
increased IGFBP-3 fragmentation and those obtained from
patients with normal protease activity were compared with use of
the Mann-Whitney Rank-Sum Test. Correlations between different
parameters were tested for using the SYSTAT program on a
Macintosh computer. Univariate analyses were done using the
Pearson correlation coefficient, while multivariate regression was
performed using a general linear model following appropriate
testing for co-linearity based on eigenvalues. 
Table 1 Age and stage distribution of the patients included in the study. n = number of patients in each group. Age is given as its median value (with range).
DCIS; ductal carcinoma in situ 
Stage (AJCC/ UICC)  n Age (years, median with range)  Subgroups  Treatment 
Benign 8  46.5  (35–59)  Excision 
Stage 0 (DCIS)  4  67.5 (46–76)  Excision 
Stage I  19  69 (46–86)  Lumpectomya / mastectomy 
Stage II  45  66 (39–88)  IIA (n = 19)  Lumpectomya/mastectomy 
(T2N1)2 IIB (n = 26)  Lumpectomy/mastectomy + adjuvant therapy  
Primary chemotherapy + surgery (T3N0)a b
Stage III  37  64.5 (55–73)  IIA (n = 21)  Primary chemotherapy + surgerya b
IIB (n = 16)  Primary chemotherapy + surgerya b
Stage IV  15  63 (55–73)  Chemotherapy or endocrine treatment depending
on oestrogen receptor (ER) status, age, and
disease severity 
aPatients treated with lumpectomy, patients with more than 4 lymph nodes with tumour infiltration, patients with T3 tumour, and all stage III patients received
postoperative radiation therapy. bPatients with ER positive tumours received adjuvant treatment with tamoxifen, age < 55 years received chemotherapy.76 SI Helle et al
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RESULTS 
IGFBP-3 proteolysis in stage I–IV breast cancer and
patients with DCIS/benign breast pathology 
Mean values of different IGFP parameters according to stage 
are given in Table 2. 19 out of 116 (16%) patients suffering from
breast cancer but 0 of 12 patients with DCIS/benign conditions
expressed elevated IGFBP-3 proteolysis. Increased IGFBP-3
proteolysis was recorded among 0/19 (0%) of patients in Stage I,
3/45 (7%) in Stage II, 9/37 (24%) in stage III, and 7/15 (47%) in
stage IV. The difference between all the stages were statistically
significant (P < 0.001) also when comparing stage I, II and III (P =
0.01). The fraction of patients with increased IGFBP-3 proteolysis
increased with increasing tumour stage (Figure 1). Patients
expressing increased IGFBP-3 proteolysis had lower levels of
IGF-I (P < 0.001), IGF-II (P < 0.001) but no difference were
observed regarding free IGF-I compared to those with ‘normal’
IGFBP-3 proteolysis. Excluding the 7 patients suffering from
conditions which possibly could influence IGFBP-3 proteolysis
(rheumatoid arthritis: n = 2, type II diabetes; n = 4, or ulcerative
colitis; n = 1) had no influence on the statistical results. 
Correlations between different IGF-parameters and
demographic variables before treatment: univariate
analysis 
Table 3 shows univariate correlations between selected IGF-para-
meters and demographic variables in all patients. A strong positive
correlation (P < 0.001) was observed between tumour stage and
patient age on the one side and IGFBP-3 proteolysis. Total IGF-I
levels correlated negatively both to age and IGFBP-3 proteolysis
(P < 0.001), while the ratio of free to total IGF-I correlated posi-
tively (P < 0.01) to the same parameters. A significant correlation
(P < 0.001) was also observed between the levels of total and free
plasma IGF-I. IGF-II correlated negatively to IGFBP-3 proteolysis
(P < 0.001) and age (P < 0.05), but neither IGF-II nor free IGF-I
correlated to tumour stage. 
Multivariate analysis 
IGFBP-3 proteolysis was positively correlated to age and tumour
stage in multivariate analysis (P < 0.01), while total IGF-I levels
correlated negatively to age and IGFBP-3 proteolysis (P < 0.01 for
both). IGF-II correlated negatively to IGFBP-3 proteolysis
(P < 0.01 for both). No significant correlation between free IGF-I
and any of the parameters was seen. Demographic and tumour-
related parameters like weight, body mass index or oestrogen
receptor status did not correlate to any of the IGF-parameters. 
DISCUSSION 
In previous studies we found IGFBP-3 fragmentation to be
increased in a significant number of patients with metastatic breast
Table 2 Pretreatment values of IGF parameters according to stage. Values are given (with the exception of IGFBP-3 proteolysis) as geometric mean with 95%
confidence intervals 
Benign/DCIS  Stage I  Stage II  Stage III  Stage IV 
IGF-I (nmol l–1)  14.7 (11.2–19.5)  10.7 (8.3–13.9)  11.2 (9.9–12.6)  13.6 (11.9–15.6)  11.0 (7.7–15.9) 
free IGF-I (nmol l–1)  0.42 (0.31–0.56)  0.36 (0.28–0.47)  0.29 (0.23–0.35)  0.39 (0.31–0.48)  0.35 (0.23–0.52) 
Ratio free IGF-I / total IGF-I (%)  2.8 (2.2–3.7)  2.7 (2.1–3.4)  2.5 (2.1–3.1)  1.7 (1.4–2.2)  1.7 (0.9–3.1) 
IGF-II (nmol l–1)  67.8 (56.4–86.5)  65.5 (54.9–78.1)  61.2 (56.8–65.9)  66.0 (59.4–73.2)  64.6 (51.3–81.3) 
IGFBP-3 proteolysisa 0.38 (0.33–0.42)  0.36 (0.33–0.39)  0.42 (0.38–0.46)  0.47 (0.41–0.53)  0.63 (0.50–0.77) 
aGiven as the ratio of fragmented to total IGFBP-3. 
Table 3 Univariate correlations (Pearson R-values) between IGF-parameters and tumour and demographic
characteristics of interest 
IGFBP-3 proteolysis  IGF-I  IGF-II free IGF-I /total IGF-I 
Stage 0.408a 0.022 0.016  –0.13 
Age 0.354a –0.367a –0.181c 0.283b
Tumour grade  0.148  –0.015  0.028  0.055 
Oestrogen receptor status –0.115  –0.033  0.023  –0.004 
Weight –0.056  0.107  0.094  –0.086 
IGFBP-3 proteolysis  –  –0.357a –0.349a 0.303a
aP < 0.001; b P < 0.01; cP < 0.05. 
P
e
r
c
e
n
t
a
g
e
0
5
10
15
20
25
30
35
40
45
50
0
I
5
IIA
Stage
IIIA IIB IIIB IV
8
14
38
47
Figure 1 The percentage of patients according to stage with elevated
IGFBP-3 proteolysis (above the 95% confidence interval of the individual
observations in our normal population of healthy premenopausal and
postmenopausal women)The IGF-system in primary breast cancer 77
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cancer (Frost et al, 1996) and also to increase or decrease in relation
to changes in tumour burden in these patients expressing elevated
protease activity (Frost et al, 1996; Helle et al, 1996). The major
aim of this study was to evaluate whether IGFBP-3 proteolysis
also may be elevated in patients suffering from primary breast
cancers with no evidence of metastasis and, if so, to evaluate a
potential correlation between tumour burden and IGFBP-3 proteo-
lysis. In addition, we wanted to evaluate the effect of elevated
IGFBP-3 proteolysis on free IGF-I levels, which has not been
determined in cancer patients previously. 
In this study, we found elevated plasma IGFBP-3 proteolysis in
12 out of 101 patients (12%) with primary breast cancer without
detectable metastases. The finding of an increasing number of
patients with elevated IGFBP-3 proteolysis among patients with
larger tumours supports our hypothesis that tumour burden may
influence IGFBP-3 proteolysis, and that this relationship also
holds in patients without overt metastatic disease. 47% of the
patients with metastatic disease at time of diagnoses had elevated
IGFBP-3 proteolysis. In a previous study 73% of patients with
metastatic breast cancer had increased IGFBP-3 protease activity
in a protease assay (using recombinant IGFBP-3) compared to
normal sera (Frost et al, 1996). However, many of the patients in
that study had a larger tumour burden and receiving second or third
line therapy, which may explain a larger number with increased
IGFBP-3 proteolysis. 
The impact of alterations in IGFBP-3 proteolysis on the disposi-
tion of IGF-I and IGF-II is difficult to interpret. We observed a
decrease in both IGF-I and -II but no difference in free IGF-I levels.
Based on these data, it is difficult to assess the effect of elevated
IGFBP-3 proteolysis on IGF-bioavailability. However, if an
elevated IGFBP-3 proteolysis reflects an increased enzyme activity
in the tissue it is tempting to speculate that the net effect is an
elevated delivery of IGF-I to the tumour cells. If IGFBP-3 proteol-
ysis acts as a growth accelerator, this could potentially explain why
some tumours achieve a stage of accelerated growth during the
process and also why a heavy tumour burden has been associated
with a poor response to therapy (Swenerton et al, 1979). Further
studies are warranted evaluating the prognostic (and possibly
predictive) value of IGFBP-3 proteolysis in breast cancer patients. 
Other investigators have previously reported increased total
IGF-I levels and an increased IGF-I/IGFBP-3 ratio in
premenopausal women with breast cancer (Bruning et al, 1995).
High total IGF-I level has recently been found to be associated
with an increased risk for development of breast cancer in
premenopausal women (Hankinson et al, 1998). While total IGF-I
may be a valid parameter for bioavailable IGF-I in healthy individ-
uals, our study indicates that analysis of total IGF-I levels should
be interpreted with caution in patients with manifest breast cancer
or other serious illnesses causing increased IGFBP-3 proteolysis. 
We conclude that a certain number of patients with primary
breast cancer express elevated protease activity for IGFBP-3, and
that this elevation correlates to tumour burden. The patient group
with increased IGFBP-3 proteolysis has lower levels of IGF-I and
-II but no difference in free IGF-I levels compared to the group
with normal IGFBP-3 proteolysis. 
ACKNOWLEDGEMENTS 
This work was supported by grants from the Norwegian Cancer
Society. The technical assistance of Mr Dagfinn Elese is highly
appreciated.
REFERENCES 
Bereket A, Lang CH, Blethen SL, Fan J, Frost RA and Wilson TA (1995) Insulin-
like growth factor binding protein-3 proteolysis in children with insulin-
dependent diabetes mellitus: a possible role for insulin in the regulation of
IGFBP-3 protease activity. J Clin Endocrinol Metab 80: 2282–2288 
Blat C, Villaudy J and Binoux M (1994) In vivo proteolysis of serum insulin-like
growth factor (IGF) binding protein-3 results in increased availability of IGF to
target cells. J Clin Invest 93: 2286–2290 
Bruning PF, van Doorn J, Bonfrer JMG, van Noord PAH, Korse CM, Linders TC
and Hart AAM (1995) Insulin-like growth factor binding protein 3 is decreased
in early-stage operable pre-menopausal breast cancer. Int J Cancer 62: 266–270 
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens
CH and Pollak M (1998) Plasma insulin-like growth factor-I and prostate
cancer risk: a prospective study. Science 279: 563–566 
Cotterill AM, Mendel P, Holly JMP, Timmins AG, Camacho-Hubner C, Cwyfan-
Hughes S, Ross RMJ, Blum WF and Langford RM (1996) The differential
regulation of the circulating levels of the insulin-like growth factors and their
binding proteins (IGFBP) 1,2 and 3 after elective abdominal surgery. Clin
Endocrinol 44: 91–101 
Davies SC, Wass JAH, Ross RJM, Cotterill AM, Buchanan CR, Coulson VJ and
Holly JMP (1991) The induction of a specific protease for insulin-like growth
factor binding protein-3 in the circulation during severe illness. J Endocrinol
130: 469–473 
Frost VJ, Helle SI, Lønning PE, van der Stappen JWJ and Holly JMP (1996) Effects
of treatment with megestrol acetate, aminoglutethimide or formestane on
insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs) and
IGFBP-3 protease status in patients with advanced breast cancer. J Clin
Endocrinol Metab 81: 2216–2221 
Guler H-P, Zapf J, Schmid C and Froesch ER (1989) Insulin-like growth factors I
and II in healthy man. Estimation of half-lives and production rates. Acta
Endocrinol 121: 753–758 
Hankinson SE, Willett WE, Colditz GA, Hunter DJ, Michaud DS, Deroo B, 
Rosner B, Speizer FE and Pollak M (1998) Circulating concentrations of
insulin-like growth factor-I and risk of breast cancer. Lancet 351: 
1393–1396 
Helle SI, Holly JMP, Tally M, Hall K, van der Stappen J and Lønning PE (1996)
Influence of treatment with tamoxifen and change in tumour burden on the
IGF-system in breast cancer patients. Int J Cancer 69: 335–339 
Huynh H, Nickerson T, Pollak M and Yang X (1996) Regulation of insulin-like
growth factor I receptor expression by the pure antiestrogen ICI 182780. Clin
Cancer Res 2: 2037–2042 
Johnson RA and Wichern DW (1982) Applied multivariate statistical analysis.
Prentice-Hall: Englewood Cliffs, New Jersey 
Jones JI and Clemmons DR (1995) Insulin-like growth factors and their binding
proteins: biological actions. Endocrine Rev 16: 3–34 
Karey KP and Sirbasku DA (1988) Differential responsiveness of human breast
cancer cell lines MCF-7 and T47D to growth factors and 17b-estradiol. Cancer
Res 48: 4083–4092 
Peyrat J-P, Bonneterre J, Beuscart R, Djiane J and Demaille A (1988) Insulin-like
growth factor receptors in human breast cancer and their relation to estradiol
and progesterone receptors. Cancer Res 48: 6429–6433 
Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, 
Lefebvre L and Demaille A (1993) Plasma Insulin-like growth factor-I 
(IGF-I) concentrations in human breast cancer. Eur J Cancer 29A: 
492–497 
Resnicoff M, Burgaud J-L, Rotman HL, Abraham D and Baserga R (1995)
Correlation between apoptosis, tumorigenesis, and levels of insulin-like growth
factor I receptors. Cancer Res 55: 3739–3741 
Swenerton KD, Legha SS, Smith T, Hortobagyi GN, Gehan EA, Yap H-Y,
Gutterman JU and Blumenschein GR (1979) Prognostic factors in metastatic
breast cancer treated with combination chemotherapy. Cancer Res 39: 1552–1562 
Turner BC, Haffty BG, Narayanan L, Yuan J, Havre PA, Gumbs AA, Kaplan L,
Burgaud J-L, Carter D, Baserga R and Glazer PM (1997) Insulin-like growth
factor-I receptor overexpression mediates cellular radioresistance and local
breast cancer recurrence after lumpectomy and radiation. Cancer Res 57:
3079–3083 
Wiseman LR, Johnson MD, Wakeling AE, Lykkesfeldt AE, May FEB and 
Westley BR (1993) Type I IGF receptor and aquired tamoxifen resistance in
oestrogen-responsive human breast cancer cells. Eur J Cancer 29A: 2256–2264 